OrthoPediatrics Corp. - KIDS STOCK NEWS

OrthoPediatrics Corp. (Nasdaq: KIDS) has announced that CEO Dave Bailey and COO/CFO Fred Hite will participate in fireside chats at two upcoming investor conferences. The first event is the Stifel 2022 Healthcare Conference on November 16, 2022, at 9:45 am ET, followed by the Piper 34th Annual Healthcare Conference on November 30, 2022, at 2:30 pm ET. Audio webcasts of these discussions will be available on the company's investor relations website, with replays accessible for 90 days post-event.

OrthoPediatrics focuses exclusively on pediatric orthopedics, offering 46 surgical systems worldwide.

OrthoPediatrics Corp. (KIDS) reported a 39% revenue increase for Q3 2022, reaching $35.0 million, driven by growth in Trauma & Deformity and Scoliosis segments.

Net income soared to $18.5 million, compared to a loss of $2.2 million a year prior. Despite external challenges, including RSV infections affecting case volumes, the company remains optimistic about sustainable growth.

Full-year revenue is projected at $124 million to $125 million, revised from an earlier estimate of $127 million to $130 million.

OrthoPediatrics Corp. (Nasdaq: KIDS) appointed Jimmy D. McDonald to its board of directors, effective October 18, 2022. McDonald, currently the Chief Supply Chain Officer at TE Connectivity, brings extensive experience in procurement and logistics, overseeing a $7.2 billion annual supplier spend. His appointment is expected to enhance OrthoPediatrics' operations, given his background in managing complex supply chains. McDonald expressed his commitment to improving children's lives through orthopedic solutions, aligning with OrthoPediatrics' mission.

OrthoPediatrics Corp. (NASDAQ: KIDS) will release its third quarter 2022 financial results on October 31, 2022, after the market closes. A conference call is scheduled for November 1, 2022, at 8:00 a.m. ET to discuss these results. The company, founded in 2006, focuses on pediatric orthopedics, offering 39 surgical systems across various categories, including trauma, scoliosis, and sports medicine. OrthoPediatrics operates in the U.S. and 70 international markets, aiming to improve pediatric orthopedic care.

OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will present at the Inaugural Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 2:00 PM ET. The company specializes in pediatric orthopedics, offering 39 surgical systems across trauma, deformity, scoliosis, and sports medicine categories. Interested parties can access the live webcast and archived presentation via the OrthoPediatrics website. Founded in 2006, the company is dedicated to improving the lives of children with orthopedic conditions, and distributes its products in the USA and 70 other countries.

OrthoPediatrics Corp. (Nasdaq: KIDS) has successfully closed its public offering of 1,091,250 shares at $55.00 each and pre-funded warrants for 1,525,000 shares at $54.99975. This transaction generated gross proceeds of approximately $144 million. The largest investor, Squadron Capital LLC, purchased the pre-funded warrants, which must be exercised upon meeting specific conditions. The net proceeds will support investments in equipment, R&D, debt repayment, and marketing efforts.

OrthoPediatrics Corp. (KIDS) announced the pricing of a public offering of 750,000 shares of common stock at $55.00 per share, alongside pre-funded warrants for an additional 1,525,000 shares. The total expected gross proceeds are approximately $125 million. These funds will be used for expanding product offerings, repaying debt, supporting R&D, and enhancing sales and marketing efforts. The offering is set to close around August 15, 2022, pending customary conditions.

OrthoPediatrics Corp. (Nasdaq: KIDS) has announced an underwritten public offering of its common stock and pre-funded warrants to purchase shares. The offering, managed by Piper Sandler and Stifel, includes a 30-day option for underwriters to purchase additional shares. Proceeds will support investments in implant and instrument sets, long-term debt repayment, research and development, and sales expansion. The securities are offered under a shelf registration statement effective since March 2020, with no assurance on completion timing due to market conditions.

OrthoPediatrics Corp. (KIDS) reported a record revenue of $32.9 million for Q2 2022, marking a 23% year-over-year increase. The company helped over 23,000 children, raising the total to 560,000. Adjusted EBITDA reached $2.1 million, up from $1.2 million in Q2 2021. Revenue from Trauma & Deformity grew 26%, while Scoliosis revenue increased 23%. The company raised its full-year revenue guidance to $127-$130 million, reflecting a 30%-33% growth compared to 2021.